Monmouth Real Estate Investment Corp (MNR) is Trading Higher on Unusual Volume for February 09

Equities Staff  |

Monmouth Real Estate Investment Corp (MNR) experienced unusually high volume on Feb. 09, as the stock gained 2.78% to a closing price of $10.74. The stock saw 352,180 shares trade hands over the course of the day on 2,846 trades. Given that the stock’s average daily volume over the last month has been 213,294 shares a day, this represents a pretty substantial spike over the norm.

Monmouth Real Estate Investment Corp has a P/B ratio of 1.99. It also has a P/E ratio of 23.2. The stock has traded between $11.99 and $9.02 over the last 52-weeks, its 50-day SMA is now $10.30, and its 200-day SMA $9.81.

Monmouth Real Estate Investment Corporation is engaged in the ownership and management of industrial buildings subject to long-term net-leases, mainly to investment grade tenants.

Headquartered in Freehold, NJ, Monmouth Real Estate Investment Corp has 15 employees and is currently under the leadership of CEO Michael P. Landy.

For a complete fundamental analysis analysis of Monmouth Real Estate Investment Corp, check out’s Stock Valuation Analysis report for MNR. To see the latest independent stock recommendations from’s analysts, visit our Research section.


The Russell 3000 is not well known outside the world of finance, but it’s one of the strongest indices out there for getting a broad sense of the stock market. Unlike the better-known Dow Jones Industrial Average or S&P 500, membership on the Russell 3000 isn’t selected by committee. It’s simply the 3,000 most valuable companies in the country.

With 3,000 stocks making up the index, it gives a broad look at the markets, including the small-and mid-cap companies that aren’t on the Dow or the S&P 500. And with a rules-based system for determining membership, there’s no bias that could potentially limit membership. That’s why many financial professionals will turn to the Russell 3000 long before the better-known indices when trying to take the temperature of the market.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change










World Economic Forum at Davos 2019 - Dr Oliver Krause Founder Untitled Inc Part 2

Matt Bird sits down with Dr Oliver Krause, Founder Untitled Inc, in part 2 of this 2 part interview at the World Economic Forum at Davos 2019

Emerging Growth

Q BioMed Inc

Q BioMed Inc is a biomedical acceleration and development company. The company is a biomedical acceleration and development company focused on licensing, acquiring and providing strategic resources to life sciences…